{
    "nctId": "NCT00867217",
    "briefTitle": "Vitamin D3 for Aromatase Inhibitor Induced Arthralgias",
    "officialTitle": "A Randomized Trial to Evaluate the Benefit of High Dose Vitamin D3 on Aromatase Inhibitor Letrozole-Associated Musculoskeletal Symptoms and Fatigue (The VITAL Trial).",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 160,
    "primaryOutcomeMeasure": "Number of Participants With Worsening of Musculoskeletal Symptoms (MS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Post-menopausal women newly diagnosed with early stage breast cancer, who would be treated with an aromatase inhibitor\n* Serum 25OHD levels \\< 40 ng/ml\n\nExclusion Criteria:\n\n* Severe or debilitating musculoskeletal pain\n* Known metastatic disease\n* History of renal stones\n* History of hypercalcemia or hyperthyroidism\n* Currently receiving adjuvant or neoadjuvant chemotherapy\n* Currently receiving other investigational agents",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}